Tilray Q4 Revenue Jumps 25% to $282M, Adjusted EPS Hits $0.05
TLRY is trading near its 52-week low of $3.8 (7.5% above the low).
Summary
Tilray's fiscal Q4 revenue surged 25% year-over-year to $281.71 million, driven by a 34% jump in international medical cannabis sales and expanding beverage and distribution segments. Adjusted EPS swung to $0.05 from $0.01 a year ago, though a net loss of $37.93 million reflected non-cash charges. Management guided for fiscal 2027 adjusted EBITDA of $68–$75 million and expects annual revenue to top $1 billion, signaling confidence in sustained growth. This follows the earlier 8-K filing today that reported record full-year revenue of $915.5 million and adjusted EBITDA of $61.1 million. The international medical cannabis platform and BrewDog acquisition are key growth engines, while U.S. regulatory uncertainty remains a headwind.
At the time of this announcement, TLRY was trading at $4.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $483.6M. The 52-week trading range was $3.80 to $23.20. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.